Kropff, Martin <br/><br/>
Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.  [electronic resource] 

 -  Haematologica  May 2012 
 - 784-91 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1592-8721 
<br/><br/><label>Standard No.: </label>10.3324/haematol.2011.044271  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Angiogenesis Inhibitors--therapeutic use<br/>Antineoplastic Agents, Hormonal--therapeutic use<br/>Dexamethasone--therapeutic use<br/>Disease Progression<br/>Drug Resistance, Neoplasm<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>International Agencies<br/>Male<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Neoplasm Recurrence, Local--drug therapy<br/>Neoplasm Staging<br/>Prognosis<br/>Prospective Studies<br/>Remission Induction<br/>Salvage Therapy<br/>Survival Rate<br/>Thalidomide--therapeutic use